Non-Percutaneous Therapies of Hepatocellular Carcinoma

  • Massimo Colombo


The adoption of stringent criteria for patient selection led to substantial improvement in the treatment outcome in patients with hepatocellular carcinoma (HCC). The relevant predictors of treatment outcome are presence or absence of cirrhosis, number and size of tumors, and degree of hepatic deterioration’. Staging is another crucial variable in treatment outcome, since many therapeutic failures have resulted from incorrect patient selection. Most tumors smaller than two cm are hypovascular and therefore escape detection with such gold standard staging techniques as biphasic spiral-CT2. For staging clinical status, the Child-Pugh scoring system provides accurate estimates of patient survival. The three year survival of untreated patients with a small tumor and well-compensated cirrhosis was approximately 25%3.


Hepatocellular Carcinoma Hepatic Resection Orthotopic Liver Transplantation Transarterial Embolization Hepatic Venous Pressure Gradient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Colombo M., 1999, Hepatocellular carcinoma: screening and treatment. In Evidence Based Gastroenterology and Hepatology (J. McDonald, A. Burroughs and B. Feagan, eds.), BMJ Books, London, pp. 456–467.Google Scholar
  2. 2.
    Oi H., Murakami T., Kim T., Matsushita M., Kishimoto H. and Nakamura H., 1996, Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. AJR 166:369–374.PubMedGoogle Scholar
  3. 3.
    Livraghi T., Bolondi L., Buscarini L., Cottone M., Mazziotti A., Morabito A. and Torzilli G., 1995, No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. J Hepatol 22:522–526.PubMedCrossRefGoogle Scholar
  4. 4.
    Ringe B., Pichlmayr R., Wittekind C. and Tush G., 1991, Surgical treatment of hepatocellular carcinoma: Experience with liver resection and transplantation in 198 patients. World J Surg 15:270–285.PubMedCrossRefGoogle Scholar
  5. 5.
    lwatsuki S., Starzl T.E., Sheahan D.G., Yokoyama I., Demetris A.J., Todo S., Tzakis A.G., Van Thiel D.H., Carr B., Selby R. and Madariaga J., 1991, Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surgery 214:221–229.CrossRefGoogle Scholar
  6. 6.
    Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A. and Gennari L., 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699.PubMedCrossRefGoogle Scholar
  7. 7.
    Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P. and Bismuth H., 1993, Liver transplantation in European patients with the hepatitis B surface antigen. N Engl JMed 329:1842–1847.CrossRefGoogle Scholar
  8. 8.
    Bain V.G., Kneteman N.M., Ma M.M., Gutfreund K., Shapiro J.A., Fischer K., Tipples G., Lee H., Jewell L.D. and Tyrrell D.L., 1996, Efficacy of Lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62:1456–1462.PubMedCrossRefGoogle Scholar
  9. 9.
    Tobe T. and Arii S., 1992, Improving survival after resection of hepatocellular carcinoma: Characteristics and current status of surgical treatment of primary liver cancer in Japan. In Primary Liver Cancer in Japan (Tobe T., Kameda H., Okudaira M., Otho M., Endo Y., Mito M., Okamoto E., Tanikawa K., Kojiro M., eds.), Springer, Tokyo, Berlin, Heidelberg, New York, London, Paris, Hong Kong, Barcelona, pp. 215–220.CrossRefGoogle Scholar
  10. 10.
    The Liver Cancer Study Group of Japan, 1994, Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74:2772–2780.CrossRefGoogle Scholar
  11. 11.
    Adachi E., Maeda T., Matsumata T., Shirabe K., Kinukawa N., Sugimachi K. and Tsuneyoshi M., 1995, Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 108:768–775.PubMedCrossRefGoogle Scholar
  12. 12.
    Nagasue N. and Yukaya H., 1989, Liver resection for hepatocellular carcinoma: Results from 150 consecutive patients. Cancer Chemother Pharmacol 23:S78–S82.PubMedCrossRefGoogle Scholar
  13. 13.
    Franco D., Capussotti L., Smadja C., Bouzari H., Meakins J., Kemeny F., Grange D. and Dellepiane M., 1990, Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology 98:733–738.PubMedGoogle Scholar
  14. 14.
    Bruix J., Castells A., Bosch J., Feu F., Fuster J., Garcia-Pagan J.C., Visa J., Bru C. and Rodes J., 1996, Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111:1018–1023.PubMedCrossRefGoogle Scholar
  15. 15.
    Llovet J.M., Fuster J. and Bruix J., 1999, for the Barcelona Clinic Liver Cancer (BCLC) Group. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434–1440.PubMedCrossRefGoogle Scholar
  16. 16.
    Harada T., Shigemura T., Kodama S., Higuchi T., Ikeda S. and Okazaki M., 1992, Hepatic resection is not enough for hepatocellular carcinoma. A follow-up study of 92 patients. Am J Gastroenterol 14:245–250.Google Scholar
  17. 17.
    Pelletier G., Roche A., Ink O., Anciaux M.L., Derhy S., Rougier P., Lenoir C., Attali P. and Etienne J.P., 1990, A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181–184.PubMedCrossRefGoogle Scholar
  18. 18.
    Groupe d’Etude et de Traitment du Carcinome Hépatocellulaire, 1995, A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261.CrossRefGoogle Scholar
  19. 19.
    Pelletier G., Ducreux M., Gay F., Luboinski M., Hagege H., Dao T., Van Steenbergen W., Buffet C., Rougier P., Adler M., Pignon J.P., Roche A., 1998, Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 28:129–134.CrossRefGoogle Scholar
  20. 20.
    Bruix J., Llovet J.M., Castells A., Montana X., Bru C., Ayuso M.C., Vilana R. and Rodes J., 1998, Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized controlled trial in a single institution. Hepatology 27:1578–1583.PubMedCrossRefGoogle Scholar
  21. 21.
    Matsui O., Kodoya M., Yoshikawa J., Gabata T., Arai K., Demachi H., Miyayama S., Takashima T., Unoura M. and Kogayashi K., 1993, Small hepatocellular carcinoma: Treatment with subsegmental transcatheter arterial embolization. Radiology 188:79–83.PubMedGoogle Scholar
  22. 22.
    Lai C.L., Wu P.C., Chan G.C.B., Lok A.S.F., Lin H.J., 1988, Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479–483.PubMedCrossRefGoogle Scholar
  23. 23.
    Farinati F., Salvagnini M., De Maria N., Fornasiero A., Chiaramonte M., Rossaro L. and Naccarato R., 1990, Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. JHepatol 11:297–301.CrossRefGoogle Scholar
  24. 24.
    Martinez Cerezo F.J., Tomas A., Donoso L., Enriquez J., Guarner C., Balanzo J., Martinez Nogueras A. and Vilardell F., 1994 Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 20:702–706.PubMedCrossRefGoogle Scholar
  25. 25.
    Elba S., Giannuzzi V., Misciagna G., Manghisi O.G., 1994, Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gatroenterology 26:66–68.Google Scholar
  26. 26.
    Castells A., Bruix J., Bru C., Ayuso C., Roca M., Boix L., Vilana R. and Rodes J., 1995, Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 109:917–22.PubMedCrossRefGoogle Scholar
  27. 27.
    CLIP Group, 1998, Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 352:17–20.CrossRefGoogle Scholar
  28. 28.
    Villa E., Camellini L., Dugani A., Zucchi F., Grottola A., Merighi A., Buttafoco P., Losi L. and Manenti F., 1995, Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 55:498–500.PubMedGoogle Scholar
  29. 29.
    Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moshandrea J. and Monousos O.N., 1998, Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42:442–447.PubMedCrossRefGoogle Scholar
  30. 30.
    Llovet J.M., Sala M., Castells L., Suarez Y., Vilana R., Bianchi L., Ayuso C., Vargas V., Rodes J. and Bruix J., 2000, Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31:54–58.PubMedCrossRefGoogle Scholar
  31. 31.
    Lawrence T.S., Tesser R.J., Tam Haken R.K., 1991, An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. Int J Radiat Oncol Biol Phys 20:555–561.PubMedCrossRefGoogle Scholar
  32. 32.
    Matsuzaki Y., Osuga T., Saito Y., Chuganji Y., Tanaka N., Shoda J., Tsuji H., Tsujii H., 1994, A new, effective and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 106:1032–1041.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Massimo Colombo
    • 1
  1. 1.Division of Internal Medicine and Fondazione Italiana Ricerca Cancro (FIRC) Center on Liver Tumors, A.M. & A. Migliavacca Center for Liver DiseasesUniversity of Milan and IRCCS Maggiore Hospital, Via Pace 9MilanItaly

Personalised recommendations